Jon Kuwahara Sells 5,276 Shares of Novus Therapeutics Inc (NVUS) Stock

Novus Therapeutics Inc (NASDAQ:NVUS) insider Jon Kuwahara sold 5,276 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $1.95, for a total transaction of $10,288.20. Following the sale, the insider now owns 7,032 shares in the company, valued at approximately $13,712.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

NASDAQ NVUS traded down $0.19 on Thursday, hitting $1.71. 3,000 shares of the stock were exchanged, compared to its average volume of 79,340. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.03. Novus Therapeutics Inc has a fifty-two week low of $1.52 and a fifty-two week high of $8.61. The stock has a market capitalization of $17.92 million, a PE ratio of -1.14 and a beta of 3.32.

Novus Therapeutics (NASDAQ:NVUS) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). On average, equities research analysts expect that Novus Therapeutics Inc will post -1.61 earnings per share for the current fiscal year.



A number of institutional investors have recently made changes to their positions in the business. Seelaus Asset Management LLC purchased a new position in shares of Novus Therapeutics in the 1st quarter valued at about $40,000. Morgan Stanley grew its stake in Novus Therapeutics by 5,676.8% in the 1st quarter. Morgan Stanley now owns 12,189 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 11,978 shares during the last quarter. National Asset Management Inc. grew its stake in Novus Therapeutics by 32.8% in the 1st quarter. National Asset Management Inc. now owns 159,705 shares of the biopharmaceutical company’s stock valued at $643,000 after acquiring an additional 39,486 shares during the last quarter. Renaissance Technologies LLC grew its stake in Novus Therapeutics by 28.6% in the 3rd quarter. Renaissance Technologies LLC now owns 251,556 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 55,968 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Novus Therapeutics by 73.5% during the 3rd quarter. Vanguard Group Inc. now owns 135,599 shares of the biopharmaceutical company’s stock worth $633,000 after purchasing an additional 57,450 shares during the last quarter. Institutional investors own 36.09% of the company’s stock.

Several analysts have recently issued reports on NVUS shares. Zacks Investment Research lowered shares of Novus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. ValuEngine upgraded shares of Novus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $10.00 target price on shares of Novus Therapeutics in a research note on Wednesday, May 15th.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://dakotafinancialnews.com/2019/05/23/jon-kuwahara-sells-5276-shares-of-novus-therapeutics-inc-nvus-stock.html.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

Further Reading: What is Put Option Volume?

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.